$3B Merck expansion makes big impact in Shenandoah Valley

Jay Langston still has a hard time comprehending the scope of the investment announced by Merck & Co. last October.

The pharmaceutical company’s $3 billion small-molecule manufacturing plant in Rockingham County is a major development for the region, the executive director of the Shenandoah Valley Partnership says, with 500 permanent jobs expected and up to 8,000 local construction jobs.

Dubbed the Center of Excellence for Pharmaceutical Ingredients and Small Molecule Manufacturing, the facility will manufacture small-molecule therapies, drugs that can be formulated into pills.

Merck started construction in October 2025 on the 400,000-square-foot manufacturing facility in Elkton. Spokesperson Ned Ehrbar says initial construction is set to be done by the end of 2028, with production beginning in 2029.

“[Merck’s] last investment in 2019 was the biggest project we ever had, and now that one seems small in comparison to what they’re doing here now,” says Langston, referring to the company’s $1 billion expansion to boost local production of HPV vaccines. “This is by far the largest project of investment in the history of the valley.”

In a statement last October, then-Gov. Glenn Youngkin called the expansion a “giant leap forward for both America’s and Virginia’s life sciences sector.”

Along with data center projects and large Virginia investments from AstraZeneca and Eli Lilly, Merck’s expansion is among the state’s biggest deals announced in 2025, according to data from the Virginia Economic Development Partnership.

Of the 500 full-time jobs, Ehrbar says, roles include operations, quality, automation and engineering.

The construction and permanent workforce are expected to drive local revenue through spending at nearby businesses and restaurants. Josh Gooden, economic and tourism director for Rockingham County, points to measurable increases in meal tax revenue as a direct result of contractor activity from previous expansions.

Ehrbar says Merck’s 85-year history in Elkton led to its decision to build the new facility there.

“The employee population at our Elkton site has long exemplified the experience, capability and flexibility necessary to succeed, having supported the manufacture of products across the breadth of our pipeline over its nearly 85-year history,” Ehrbar says.

Gooden says Merck’s history in the valley has built trust in the community through its nearly century-long commitment.

“My granddad worked at Merck and retired from there,” Gooden says. “It’s hard to find a person who doesn’t have some connection to somebody who either works at Merck or worked at Merck.”

The company also had practical reasons for expanding in Elkton. The area had available square footage to grow Merck’s footprint.

Merck already has a 1.1-million-square-foot facility in Elkton, employing more than 1,000 people, including some hired after the 2019 expansion.

Through previous growth, Merck has drawn on the region’s talent pipeline, making the presence of institutions like James Madison University, the University of Virginia, Bridgewater College and Blue Ridge Community College a key factor in the company’s decision.

The new facility will produce different jobs in automation, engineering and quality testing, which Merck will rely on local educational partners and the state’s Virginia Talent Accelerator Program to produce. This educational commitment is a vital part of the economic “spider web” the facility will spin into the community, Langston says.

Langston emphasized this commitment secures high value, “bread and butter” manufacturing jobs for the county, providing stability amid other investments.

“This is a fairly small community, and this deal will make a big impact not just with the investment by Merck but with the residual effect of the contractors employed while constructing the facility,” Gooden adds.

In addition to state incentives, Rockingham County offered a machinery and tools rebate for the project, easing the company’s tax burden. Gooden says the rebate to Merck could total about $51 million over five to six years. The state approved a $5 million capital boost from the Virginia Investment Performance grant and a $4 million Commonwealth’s Opportunity Fund grant to aid the county.

Headquartered in New Jersey, Merck reported $64.16 billion in 2024 sales, up from $60.11 billion in 2023. Merck says its Elkton work is part of a $70 billion investment started in 2025 to expand domestic manufacturing and R&D. The company announced other projects in North Carolina, Delaware and Kansas in early 2025.